Business Divisions:
a) New Drug Discovery: ^{[1] [2]}
The company’s New Drug Discovery
programme focuses on developing
novel antibiotics to address the
growing threat of antimicrobial
resistance (AMR) and unmet
needs in treating MDR and
XDR infections. It follows a
“discovery-to-delivery”
approach, advancing
first-in-class and
differentiated
antibiotics
from research
and clinical
development
to commercialisation
across India and inter
national markets. During
FY26, 5 novel antibiotics,
including Emrok, Emrok
O, Miqnaf, Zaynich, and
Foviscu, completed Phase
3 development, while Odrate
progressed to Phase 2. The
portfolio covers infections
including MRSA, ESBL-producing
and carbapenem-resistant pathogens, pneumonia and complicated urinary
tract infections.
b) Branded Pharmaceuticals:^[3]
The company is engaged in the
development, manufacturing, and
marketing of finished formulations, biopharmaceuticals, branded generics,
OTC, and prescription products across
various therapeutic segments. Its key biopharmaceutical products include
Glaritus, Wosulin, Wepox, and recombinant human insulin. It ranks among the Top 3
in around 20 products in the US, among
theTop 5 generic companies in the UK,
and as the largest ** generic company in
Ireland’s hospital segment.
c) Contract Manufacturing: ^[4]
The company offers contract manufacturing services from product development to high-volume commercial manufacturing. Its full
turnkey service is supported by experienced teams across development, technology transfer, manufacturing, quality assurance, regulatory affairs, logistics, engineering, and purchasing.
d) Biosimilar: ^[5][6]
The company focuses on developing
and manufacturing biosimilar and bio
better products, with diabetes as a
key focus area. Its portfolio includes
rapid, fast, and long-acting insulin
formulations, available in vials and
cartridges, along with patented
insulin pens. It has applied for
118 biotech product patents
globally and holds 57 patents
in the biosimilar and bio-better
development phase, out of which
23 patents are for the company’s
insulin pen globally. In FY26, the
company has obtained patents
in 10 European countries
for its new combination drug
product.
e) Vaccines:^[7][8]
The company manufactures vaccines across its UK and India facilities. Its Wrexham facility has manufactured the AstraZeneca-Oxford COVID-19 vaccine, and the company has partnered with the Serum Institute of India for vaccine manufacturing in the UK. Its Indian facilities are approved for vaccine manufacturing and exports of up to 1 Bn doses.
f) API:^[9]
The company manufactures complex APIs and formulations and has developed 140+ US ANDAs and 60+ EU CTD dossiers, covering multiple dosage forms and niche products. It is also among the largest** manufacturers of Dextromethorphan HBr API globally and explores licensing opportunities across the US and Europe.